Novel diagnostic and therapeutic frontiers in thrombotic anti-phospholipid syndrome

详细信息    查看全文

• 作者：Savino Sciascia ; Massimo Radin ; Mario Bazzan…
• 关键词：APS ; Thrombosis ; Pregnancy morbidity ; aPL
• 刊名：Internal and Emergency Medicine
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：12
• 期：1
• 页码：1-7
• 全文大小：
• 刊物主题：Internal Medicine;
• 出版者：Springer Milan
• ISSN：1970-9366
• 卷排序：12

文摘

The anti-phospholipid syndrome (APS) is an autoimmune disorder characterized by vascular thrombosis and/or pregnancy morbidity, associated with a persistent positivity for anti-phospholipid antibodies (aPL). The current classification criteria for APS include three laboratory tests: lupus anti-coagulant (LA), anti-cardiolipin (aCL), and anti-β2 glycoprotein-I (β2GPI). To date, the therapeutic approach for thrombotic APS mainly centers on long-term anti-coagulation with a vitamin K antagonist (VKA). APS management may represent a challenge for the treating physicians. Patients with different aPL profiles need a tailored risk-stratified approach. Moreover, in patients with recurrent thrombotic events despite therapy with VKA, or in those with microvascular involvement, new therapeutic options are highly needed. In this review, we aim to elucidate recent findings about new aPL specifities, available risk scoring models, and novel therapeutic approaches in APS management.